Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06503653
Active, not recruiting Not applicable

Creation of a Syncope Channel for Patients Admitted to the Emergency Department for Loss of Consciousness and Not Hospitalized: Etiological Predictivity (Before/After Study)

NCT06503653 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-03-31
Last updated
2025-04-10

Condition(s) studied

Syncope

Investigational drug(s) / intervention(s)

syncope channelroutine care

syncope channel: The procedures and investigations proposed for the etiological diagnosis of low-risk or "neither high nor low" syncope and included in the study are those recommended by the European Society of Cardiology. No additional procedures, invasive or non-invasive explorations or blood sampling not provided for as part of routine care will be offered or carried out as part of the study. The only change in practice for patients included in the "syncope pathway The only change in practice concerns the grouping of patients included in the "syncope pathway" into a single day at a day hospital within 10 days of their emergency consultation.

routine care: The procedures and investigations proposed for the etiological diagnosis of low-risk or "neither high nor low" syncope and included in the study are those recommended by the European Society of Cardiology.in routine care, medical examinations are carried out by specialists such as cardiologists who do not practice in hospitals

Study summary

The main aim of this study is to assess the value of creating a "syncope pathway" to optimize diagnostic performance in patients admitted to the emergency department for syncope and not hospitalized, compared with the previous pre-syncope pathway situation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 and over; * Consultant at the emergency department of the Centre Hospitalier de V ersailles * For a confirmed diagnosis: * of recurrent syncope with low-risk criteria according to ESC 2018 (1,2) Or * of syncope recurrent or not, not fulfilling low-risk or high-risk criteria according to the ESC 2018 definition (1,2). These patients are those with minor high-risk criteria without aggravating circumstances: * With no personal history of loss of consciousness whose clinical features strongly suggest syncope of rhythmic origin; * No structural heart disease or abnormal ECG. * Outpatient (returning home after emergency); * Beneficiary or beneficiary of a social security scheme (excluding AME). Exclusion Criteria: * Etiology of syncope identified as early as the emergency department visit; * High-risk syncope according to ESC 2018 criteria (1,3); * First and only episode of low-risk syncope according to ESC 2018 criteria (1,3); * Syncope of any risk category requiring hospitalization at the discretion of the emergency physician and cardiologist; * Legal protection by guardianship ; * Language barrier or condition incompatible with the patient's understanding or informed adherence to the protocol; * Opposition to the use of their pseudonymized data (for retrospective inclusions); * Patient's refusal to give consent to participate in the study (for prospective inclusions);

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
centre hospitalier de Versailles Le Chesnay Yvelines

More Versailles Hospital trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06503653 on ClinicalTrials.gov ↗ ← All trials in France